Immunotherapy for cancer: promoting innate immunity

Area of Science:

• Immunology
• Oncology
• Pathophysiology

Background:

• Tumor development over years causes reciprocal immune and tumor alterations, paradoxically enabling tumor growth during necrosis and inflammation.
• Innate immune cells (granulocytes, mast cells) are the first defense, sensing pathogen/damage signals and initiating inflammation.
• Current cancer immunotherapies primarily target the adaptive immune response, overlooking innate immunity's role.

Purpose of the Study:

• To explore the impact of acute and chronic inflammation on tumor development.
• To understand the pathophysiology of immunity in cancer, focusing on granulocytes and mast cells.
• To investigate novel strategies for limiting tumor progression by targeting innate immune responses.

Main Methods:

• Analysis of tumor-induced immune alterations.
• Review of inflammatory processes in cancer.
• Examination of granulocyte and mast cell functions in tumor settings.

Main Results:

• Highly evolved adult tumors undergo necrosis, releasing damage-associated molecular patterns (DAMPs).
• DAMPs promote tumor growth via reactive angiogenesis, stromagenesis, and epithelial proliferation.
• Peroxidases from innate immune cells can aerobically eliminate DAMPs, suggesting therapeutic potential.

Conclusions:

• Innate immune cells, particularly granulocytes, play a critical role in cancer development and progression.
• Managing inflammation and DAMPs through innate immune effectors presents a novel therapeutic avenue.
• Further research into innate immunity modulation is crucial for advancing cancer immunotherapy.